Is AbbVie Stock Underperforming the Dow?

North Chicago, Illinois-based AbbVie Inc. (ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. With a market cap of $311.4 billion, the company discovers and develops medicines and therapies that solve health issues across immunology, oncology, aesthetics, neuroscience, and eye care. 

Companies worth $200 billion or more are generally described as “mega-cap stocks,” and ABBV definitely fits that description, with its market cap exceeding this threshold, reflecting its substantial size, influence, and dominance in the general drug manufacturers industry. ABBV stands out in the fields of immunology and oncology, with popular products like Humira, Skyrizi, and Rinvoq solidifying its market position. The recent approvals of Skyrizi for ulcerative colitis and Rinvoq for pediatric patients with arthritis showcase AbbVie's dedication to addressing medical needs. Through strategic acquisitions of companies like ImmunoGen and Cerevel Therapeutics, AbbVie continues to expand its oncology pipeline and enhance its therapeutic offerings.